Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $35.7647 (3.22%) ($34.3140 - $36.3300) on Thu. Jul. 20, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.07% (three month average) | RSI | 13 | Latest Price | $35.7647(3.22%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.7% a day on average for past five trading days. | Weekly Trend | HTBX declines -8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKK(8%) KWEB(8%) MCHI(8%) QQQ(8%) SKYY(8%) | Factors Impacting HTBX price | HTBX will decline at least -2.035% in a week (0% probabilities). VCSH(-9%) VIXM(-5%) CEMB(-5%) BNDX(-4%) XLU(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.035% (StdDev 4.07%) | Hourly BBV | 0 () | Intraday Trend | 2.2% | | | |
|
1 - 5 Day Possible Target | $20.91(-41.53%) | Resistance Level | $39.9 | 5 Day Moving Average | $36.24(-1.31%) | 10 Day Moving Average | $37.34(-4.22%) | 20 Day Moving Average | $39.9(-10.36%) | To recent high | -35.1% | To recent low | 3.2% | Market Cap | $3.935b | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |